Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada

YJ Kim, M Oremus, HH Chen, T McFarlane… - …, 2021 - Springer
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
被引用次数：8 相关文章

Cost‑Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First‑Line Treatments for EGFR Mutation‑Positive Non‑Small‑Cell Lung Cancer in Ontario, Canada

YJ Kim, M Oremus, HH Chen, T McFarlane… - …, 2021 - search.proquest.com
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

YJ Kim, M Oremus, HH Chen… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

YJ Kim, M Oremus, HH Chen, T McFarlane… - …, 2021 - ideas.repec.org
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

YJ Kim, M Oremus, HH Chen, T McFarlane… - …, 2021 - econpapers.repec.org
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.

YJ Kim, M Oremus, HH Chen, T McFarlane… - …, 2021 - europepmc.org
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …